Location · Houston, TX
Clinical trials in Houston, TX
838 recruiting studies have a site in the Houston area, and 205 of them accept healthy volunteers. The area includes Pasadena, Sugar Land, The Woodlands, Katy, Pearland, Baytown and nearby cities.
838 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Merck Sharp & Dohme LLC
- Location
- Chandler, AZ + 35 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
W.L.Gore & Associates
- Location
- Scottsdale, AZ + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sanofi
- Location
- Birmingham, AL + 70 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Biogen
- Location
- Loma Linda, CA + 24 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
PureTech
- Location
- Palm Spring, CA + 15 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Renibus Therapeutics, Inc.
- Location
- Chula Vista, CA + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals
- Location
- Denver, CO + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Ipsen
- Location
- Chandler, AZ + 20 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Phoenix, AZ + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Pelham, AL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Alexander City, AL + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Gilbert, AZ + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Waterford, CT + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels
Gilead Sciences
- Location
- Ft. Pierce, FL + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Adneuris Therapeutics, Inc.
- Location
- Phoenix, AZ + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
Adneuris Therapeutics, Inc.
- Location
- North Canton, OH + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
- Location
- Avondale, AZ + 10 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell…
Incyte Corporation
- Location
- Palo Alto, CA + 29 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Birmingham, AL + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Oceanside, CA + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Regeneron Pharmaceuticals
- Location
- La Mesa, CA + 35 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Peptilogics
- Location
- Sarasota, FL + 13 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Generate Biomedicines
- Location
- Northridge, CA + 35 other US sites
- Eligibility basics
- Ages 12–80
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Vima Therapeutics
- Location
- Birmingham, AL + 36 other US sites
- Eligibility basics
- Ages 18–70